Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
doi: 10.3390/jcm13082176
AOD-9604 and Tesamorelin in Combination Research The theoretical basis for discussing AOD-9604 alongside Tesamorelin comes from their non-overlapping mechanisms: AOD-9604 acts locally on fat tissue without engaging the GH/IGF-1 axis, while Tesamorelin works upstream by stimulating pituitary GH release
Use should be discontinued upon observing any adverse reaction
Typical ranges: BPC-157 at 250 to 750 mcg/day, semaglutide at 0.25 to 2.4 mg/week, CJC-1295 at 100 to 200 mcg per injection, and TB-500 at 2 to 5 mg twice weekly
Test before you start and again at 48 weeks
Larsen, MD
